Literature DB >> 5050398

Use of confidence intervals in analysis of comparative bioavailability trials.

W J Westlake.   

Abstract

Mesh：

Substances：

Year:  1972        PMID： 5050398     DOI： 10.1002/jps.2600610845

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  41 in total

1.  Plasma concentrations, bioavailability and dissolution of chlorpropamide.

Authors:  T Taylor; D F Assinder; L F Chasseaud; P M Bradford; J S Burton
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

2.  Urinary excretion: does it accurately reflect relative differences in bioavailability/systemic exposure when renal clearance is nonlinear?

Authors:  Gary A Thompson; Roger D Toothaker
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

3.  Order effects in the assessment of quality of life in cancer patients.

Authors:  Yin-Bun Cheung; Lea-Choung Wong; Miah-Hiang Tay; Chee-Keong Toh; Wen-Hsin Koo; Richard Epstein; Cynthia Goh
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

4.  Comparative bioavailability study of two brands of prazosin-containing tablets in healthy volunteers.

Authors:  P J Guelen; T J Janssen; M H Lam; T B Vree; P S Exler
Journal:  Pharm Weekbl Sci       Date:  1990-10-19

5.  Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et al.

Authors:  John B Warren; Kersti Oselin
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

6.  Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.

Authors:  J Popović; R Mitić; A Sabo; M Mikov; V Jakovljević; K Daković-Svajcer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

7.  Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers.

Authors:  G M Leggio; T Incognito; G Privitera; M R Marano; F Drago
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

8.  Comparison of the bioavailability of two slow release preparations of disopyramide.

Authors:  M G Bogaert; F Belpaire; G De Wilde; R A Lefebvre
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests.

Authors:  H A Heck; S E Buttrill; N W Flynn; R L Dyer; M Anbar; T Cairns; S Dighe; B E Cabana
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

10.  Relative bioavailability of commercial ampicillin formulations in man.

Authors:  M Mayersohn; L Endrenyi
Journal:  Can Med Assoc J       Date:  1973-11-17       Impact factor: 8.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.